All In Biotech

Free tool

FAERS Monitor: Invega Sustenna

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022264 or its brand name (Invega Sustenna, Paliperidone Palmitate). Reports on generic versions are filed under their own applications.

Reports

28,106

Serious

12,195

43% of reports

Hospitalization

5,908

Death reported

1,104

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use3,059
  • drug ineffective1,783
  • hospitalisation1,667
  • weight increased1,601
  • drug dose omission1,339
  • product dose omission issue1,153
  • gynaecomastia1,065
  • schizophrenia897
  • treatment noncompliance891
  • blood prolactin increased855
  • incorrect dose administered806
  • psychotic disorder740
  • inappropriate schedule of drug administration739
  • condition aggravated717
  • galactorrhoea657

Reports by year received

View as table
YearReports
20062
20071
20081
200926
2010640
20111,000
20121,510
20131,560
20141,509
20151,658
20161,579
20172,433
20181,719
20191,689
20201,509
20211,601
20222,388
20231,904
20241,855
20251,839
20261,683

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,053 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood prolactin increasedSignal855165.5153.8114,359
galactorrhoeaSignal65785.178.648,987
schizophreniaSignal89759.655.747,814
gynaecomastiaSignal1,06526.625.125,394
psychotic disorderSignal74019.217.912,455
treatment noncomplianceSignal89112.411.69,175
hospitalisationSignal1,6678.27.810,489
inappropriate schedule of drug administrationSignal7397.87.34,376
drug dose omissionSignal1,3396.15.85,707
weight increasedSignal1,6015.45.15,727
product dose omission issueSignal1,1532.92.81,491
incorrect dose administeredSignal8062.62.5831
off label useSignal3,0592.62.53,184
condition aggravated7171.81.6241
drug ineffective1,7831.01.00

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.